The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).
Pamela N. Munster
Research Funding - Novartis
Erika Paige Hamilton
No relevant relationships to disclose
Catherine Franklin
Employment or Leadership Position - Novartis
Suraj Bhansali
Employment or Leadership Position - Novartis
Kitty Wan
Employment or Leadership Position - Novartis
Becker Hewes
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Dejan Juric
Consultant or Advisory Role - Novartis